source
- #ASGCT26: Tessera reveals strongest data yet for in vivo sickle cell therapyBOSTON — Tessera Therapeutics has created an experimental gene editing drug for sickle cell disease that could compete with commercial cell therapies but is delivered as an infusion — no complex ce…Endpoints · 2mo ago↗ source
- How Reimagined Research Endeavors Intersect With Dignified End-of-Life Care: With D. Ross Camidge, MD, PhD; and Charles D. Blanke, MD, FACP, FASCODrs Camidge and Blanke discuss Dr Blanke's career path from pioneering targeted cancer therapies to becoming a leading advocate for medical aid in dying.onclive · 2mo ago↗ source
- BRUIN CLL-321 Trial Impact and Treatment SelectionExperts outline relapse workup in CLL, using PET-CT and biopsy for suspected Richter’s, plus resistance and TP53 testing to guide next therapy.